Atherogenesis in renal patients: a model of vascular disease?
- PMID: 18393910
- DOI: 10.2174/157016108783955374
Atherogenesis in renal patients: a model of vascular disease?
Abstract
Chronic kidney disease (CKD), and particularly kidney failure, is associated with accelerated atherosclerosis and approximately a 20-fold increased risk of cardiovascular death. The majority of these patients die from complications directly attributed to atherosclerosis and their life expectancy is decreased. Established risk factors are involved in the pathogenesis of this phenomenon. Age, gender, smoking, hypertension, dyslipidaemia and diabetes mellitus are among the established risk factors. Inflammation, qualitative lipid disorders (e.g. small dense low density lipoprotein), vascular calcification and oxidative stress represent emerging risk factors. The precise mechanism of atherosclerosis in patients with kidney failure is not yet known. CKD might represent a clinical model of atherogenesis. Thus, the evidence obtained from investigating "renal" atherogenesis could be of interest in improving our understanding of this disease process in the non-renal population. We review the relationship between "renal" and non-renal atherosclerosis focusing on pathogenesis, risk factors and clinical events and how they interact with treatment options. Overall, the "later" stages of CKD may eventually be considered as a coronary heart disease equivalent condition.
Similar articles
-
[Vascular risk factors and renal failure].Med Sci (Paris). 2004 Dec;20(12):1100-3. doi: 10.1051/medsci/200420121100. Med Sci (Paris). 2004. PMID: 15581463 Review. French.
-
[Vascular damage in chronic kidney disease].Rev Med Chil. 2008 Nov;136(11):1476-84. doi: 10.4067/s0034-98872008001100016. Rev Med Chil. 2008. PMID: 19301781 Review. Spanish.
-
Cardiovascular calcification in nondialyzed patients with chronic kidney disease.Semin Dial. 2007 Mar-Apr;20(2):134-8. doi: 10.1111/j.1525-139X.2007.00260.x. Semin Dial. 2007. PMID: 17374087 Review.
-
The role of oxidative stress-altered lipoprotein structure and function and microinflammation on cardiovascular risk in patients with minor renal dysfunction.J Am Soc Nephrol. 2004 Mar;15(3):538-48. doi: 10.1097/01.asn.0000111744.00916.e6. J Am Soc Nephrol. 2004. PMID: 14978155 Review.
-
Atherosclerosis and vascular calcification in chronic renal failure.Kidney Blood Press Res. 2005;28(5-6):280-9. doi: 10.1159/000090182. Epub 2006 Mar 7. Kidney Blood Press Res. 2005. PMID: 16534222 Review.
Cited by
-
IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis.Arch Med Sci. 2011 Dec 31;7(6):984-92. doi: 10.5114/aoms.2011.26610. Epub 2011 Dec 30. Arch Med Sci. 2011. PMID: 22328881 Free PMC article.
-
Evaluation of the Relationship Between Microalbuminuria and Urine Ischemia-Modified Albumin Levels in Patients with Diabetic Nephropathy.J Clin Lab Anal. 2017 May;31(3):e22058. doi: 10.1002/jcla.22058. Epub 2016 Oct 1. J Clin Lab Anal. 2017. PMID: 27696561 Free PMC article.
-
High-density lipoprotein: quantity or quality?J Thorac Dis. 2016 Nov;8(11):2975-2977. doi: 10.21037/jtd.2016.11.67. J Thorac Dis. 2016. PMID: 28066561 Free PMC article. No abstract available.
-
Role of Resveratrol on Indoxyl Sulfate-Induced Endothelial Hyperpermeability via Aryl Hydrocarbon Receptor (AHR)/Src-Dependent Pathway.Oxid Med Cell Longev. 2019 Nov 27;2019:5847040. doi: 10.1155/2019/5847040. eCollection 2019. Oxid Med Cell Longev. 2019. PMID: 31885805 Free PMC article.
-
Paraoxonase-1 and ischemia-modified albumin in patients with end-stage renal disease.J Physiol Biochem. 2011 Sep;67(3):437-41. doi: 10.1007/s13105-011-0092-4. Epub 2011 Apr 12. J Physiol Biochem. 2011. PMID: 21484479 Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical